ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Tea drinkers have lower glaucoma risk

Why Is Chlorella Considered a Superfood?

Soy, cruciferous vegetables could help lower breast cancer treatment side effects

The Long-Term Benefits of Drinking Oolong Tea

Wonderful White Tea: A Drink Fit for an Emperor

Why You Should Try This Sweet-Smelling and Health-Boosting Essential Oil

Arnica: This Powerful Herb Promotes Various Kinds of Healing

Chamomile Tea: Why This Ancient Therapeutic Drink Still Stands Out Today

Get ‘Hooked’ on Cat’s Claw: The Many Benefits of This Amazonian Herb

Try Apple Cider Vinegar and Black Cumin Oil as Your Go-To Salad Dressing

 
Print Page
Email Article

Enbrel® is First Therapy Shown to Inhibit Bone and Joint Damage in Psoriatic Arthritis

  [ 35 votes ]   [ Discuss This Article ]
www.ProHealth.com • December 4, 2002


Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of structural damage in patients with psoriatic arthritis. These radiographic results were presented as part of an oral presentation at the 66th American College of Rheumatology Annual Scientific Meeting in New Orleans.

"ENBREL is the first therapy to reduce signs and symptoms, and inhibit the progression of bone erosions and joint space narrowing associated with psoriatic arthritis, a disease which has unique and distinct radiographic features not seen in rheumatoid arthritis," said Dr. Peter Ory, department of radiology, University of Washington, and lead investigator of the study. "Patients with psoriatic arthritis often exhibit the painful bone and joint destruction and eventual deformities to fingers, hands and wrists which are associated with disability in this disease."

ENBREL is approved to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis.

A phase 3 study evaluated 205 patients with active psoriatic arthritis who also had stable psoriasis. Patients first completed a 6-month placebo-controlled blinded portion, then were eligible to enter a 48 week open-label study with ENBREL (25-mg twice-weekly subcutaneous injections). A primary endpoint of the study was determination of radiographic progression in patients treated with ENBREL versus placebo. X-rays of patients' hands and wrists were obtained at baseline, 6 months, upon rollover to active drug and at 12 months.

At one year, there was inhibition of radiographic progression in the ENBREL group (n=101) compared with the placebo group (n=104). The mean change from baseline in total Sharp score (TSS) was a reduction in progression of –0.03 units in the ENBREL group versus an increase in progression of +1.00 units in the placebo group (p=0.0001). The Sharp method uses a 4-point scale to rate joints according to the severity of erosions and degree of joint space narrowing. The erosion and joint space-narrowing subscores are then added to obtain a total radiographic score.

Progression of structural damage was inhibited when measured not only by the TSS, but also by joint erosion scores and joint space narrowing scores. Mean changes from baseline in erosion scores over a year were -0.09 units in patients treated with ENBREL versus +0.66 units in the patients treated with placebo (p=0.0001). Additionally, mean changes in joint space narrowing from baseline over a year were +0.05 units in patients treated with ENBREL, versus +0.34 units in patients treated with placebo (p=0.04).

Adverse events were similar to those reported in previous clinical trials of ENBREL in patients with rheumatoid arthritis. There was no increase in the number of serious adverse events occurring in patients treated with ENBREL compared to those receiving placebo. Only the rate of injection site reactions (ISRs) in patients receiving ENBREL was statistically different compared to placebo (9% with placebo versus 36% with ENBREL in the placebo controlled segment).



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Vitamin D3 Extreme™ Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Quercetin: Natural Support for Allergy & Inflammation Relief and More Quercetin: Natural Support for Allergy & Inflammation Relief and More
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Health Benefits Are Brewing in Green Tea Health Benefits Are Brewing in Green Tea

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map